Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia.
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000191:economics; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000191:economics; D011355:Prodrugs / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D001087:Arabinonucleosides; D011355:Prodrugs; C104457:nelarabine